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OBJECTIVE — Dicarboxylic acids are natural products with the potential of being an alter-
nate dietary source of energy. We aimed to evaluate the effect of sebacic acid (a 10-carbon
dicarboxylic acid; C10) ingestion on postprandial glycemia and glucose rate of appearance (Ra)
in healthy and type 2 diabetic subjects. Furthermore, the effect of C10 on insulin-mediated
glucose uptake and on GLUT4 expression was assessed in L6 muscle cells in vitro.
RESEARCH DESIGN AND METHODS — Subjects ingested a mixed meal (50% car-
bohydrates, 15% proteins, and 35% lipids) containing 0 g (control) or 10 g C10 in addition to
the meal or 23 g C10 as a substitute of fats.
RESULTS — In type 2 diabetic subjects, the incremental glucose area under the curve (AUC)
decreased by 42% (P  0.05) and 70% (P  0.05) in the 10 g C10 and 23 g C10 groups,
respectively. At the largest amounts used, C10 reduced the glucose AUC in healthy volunteers
also.Whenfatsweresubstitutedwith23gC10,AUCofRawassigniﬁcantlyreducedontheorder
of 18% (P  0.05) in both healthy and diabetic subjects. The insulin-dependent glucose uptake
byL6cellswasincreasedinthepresenceofC10(38.710.3vs.11.45.4%;P0.026).This
increase was associated with a 1.7-fold raise of GLUT4.
CONCLUSIONS — Sebacic acid signiﬁcantly reduced hyperglycemia after a meal in type 2
diabetic subjects. This beneﬁcial effect was associated with a reduction in glucose Ra, probably
due to lowered hepatic glucose output and increased peripheral glucose disposal.
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T
he World Health Report launched in
2002 by the World Health Organi-
zation advised that more than 1 bil-
lion adults worldwide are overweight and
at least 300 million are clinically obese.
Type 2 diabetes can be considered a
threatening obesity-related disease be-
cause hyperglycemia causes relevant
complications such as micro- and mac-
roangiopathy. Patients with type 2 diabe-
tes exhibit increased hepatic glucose
output, which is identiﬁed as the main
cause of fasting hyperglycemia and is as-
sociated with impaired plasma glucose
clearance(1)andreducedhepaticsynthe-
sis of glycogen of 25–45% compared
with that in nondiabetic subjects (2). In-
creasedhepaticgluconeogenesishasbeen
considered to be responsible for elevated
hepatic glucose output in type 2 diabetes
(3). When glycogen is available in ade-
quate amounts, there is an autolimitation
of hepatic glucose production. In diabe-
tes, a breakdown of this autoregulation
may occur if glycogenolysis is limited by
glycogen depletion (4).
Jenkins et al. (5) have shown that
spreading the nutrient load over a longer
period of time by increased meal fre-
quency, the so-called nibbling diet, is
beneﬁcial in terms of reduction of circu-
lating levels of glucose, insulin, and free
fatty acids in type 2 diabetes. Thus, the
availability of snacks poor in fat and that
do not induce hyperglycemia and/or
overstimulate insulin secretion would be
agoodtoolinthedietofinsulin-resistant,
type 2 diabetic subjects.
Dicarboxylic acids are naturally oc-
curring substances produced by both
higherplantsandanimalsvia-oxidation
of fatty acids (6,7). In plants, long-chain
dicarboxylicacidsarecomponentsofnat-
ural protective polymers, cutin and
suberin, which support biopolyesters in-
volved in waterprooﬁng the leaves and
fruits, regulating the ﬂow of nutrients
amongvariousplantcellsandorgans,and
minimizing the deleterious impact of
pathogens (7). In animals and humans,
medium chain dicarboxylic acids, which
includeprevalentlysebacic(C10)anddo-
decanedioic (C12) acids, derive from the
-oxidation of longer chain dicarboxylic
acids (8). Long-chain dicarboxylic acids,
in turn, are formed from the correspon-
dent fatty acids by -oxidation in the mi-
crosomal membranes (9) or are taken in
with a diet rich in vegetables (7).
We have shown previously that me-
dium-chaindicarboxylicacidsrepresenta
suitable alternate energy substrate to glu-
cose in clinical conditions with marked
insulin resistance and/or impaired aero-
bicglycolysis(10).Interestingly,intype2
diabetes, medium-chain dicarboxylic ac-
ids are rapidly oxidized, do not stimulate
insulin secretion, and reduce muscle fa-
tigue (11). Nevertheless, the effect of C10
or C12, not as a substitute but in addition
toavailablecarbohydrates,onglucoseho-
meostasis has never been studied.
On this basis, our aim was to investi-
gate the effect of oral administration of
C10 on postprandial glycemia, insuline-
mia, and glucose rate of appearance (Ra)
in type 2 diabetic subjects compared with
that in healthy volunteers. To further elu-
cidate the mechanism of action of sebacic
acidindiabetes,insulin-mediatedglucose
uptake and GLUT4 protein expression
were assessed in L6 cells in vitro.
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METHODS— From October 2006 to
September2007,10obesetype2diabetic
subjects and 10 healthy volunteers were
enrolled.Womeninfertileagewereasked
to avoid pregnancy during the study pro-
tocol.Inaddition,beforestartingeachex-
perimental session a pregnancy test was
performed, and pregnant women were
excluded from the investigation. All
women were studied in the follicular
phase of their menstrual cycle. None of
the subjects previously or currently had
major endocrinological, renal, cardiac,
respiratory, liver, or gastrointestinal
disorders.
All subjects underwent a 75-g oral
glucosetolerancetesttomeasuretheMat-
suda index, as an index of insulin resis-
tance (12). None of the diabetic subjects
were taking oral hypoglycemic agents or
were diagnosed with type 2 diabetes 2–5
years before the study and their A1C was
5.5–7.5%.
The protocol was approved by the
ethics committee of the Catholic Univer-
sity, School of Medicine, in Rome, Italy.
All of the subjects signed a written in-
formed consent form before starting the
study.
Chemicals
Sebacic acid was purchased from Sigma-
Aldrich (St. Louis, MO) and puriﬁed by
Real s.r.l. (Como, Italy). It was pyrogen-
free and contaminant-free with a degree
of puriﬁcation (gas-liquid chromatogra-
phy/mass spectrometry) of 99.5%. 6,6-D-
Glucose was purchased from Mass Trace
(Woburn, MA).
Experimental protocol
The subjects were studied on three sepa-
rate occasions in a randomized way at a
distance of 1 month. After an overnight
fast, during which subjects were in-
structed not to drink, the study was initi-
ated at 8:00 A.M. An indwelling catheter
was placed into an antecubital vein for
isotope infusion. A second catheter was
inserted retrogradely into a wrist vein of
the ipsilateral hand, and the hand was
placedintoaheatedbox(60°C)toachieve
arterializationofvenousblood.Basalrates
ofglucoseturnoverwereassessedafter2h
ofanadjustedprimed(22mol/kg),con-
tinuous (0.22 mol kg
1 min
1) infu-
sion of 6,6-D2-glucose (Cambridge
Isotope Laboratory, Boston, MA) (13).
Two hours after the beginning of the ses-
sion, the subjects ingested a mixed meal
(see Table 1 for meal composition).
Blood samples for the determination
of 6,6-D-glucose enrichment, plasma C-
peptide, and plasma insulin concentra-
tions were obtained before the tracer
infusion was started and every 10 min
during the last 20 min of the 2 h preced-
ing the meal ingestion (equilibration pe-
riod). Starting from the meal ingestion
time,plasmasampleswereobtainedevery
20 min for 5 h. Therefore, overall the
study duration was7ho r4 2 0min.
Each subject voided to empty his/her
bladder before starting the experimental
protocol. The subsequent 24-h urine
sampleswerecollectedinacontainerwith
0.1% sodium azide to prevent bacterial
growth.
Body composition
After subjects voided and were weighed,
body composition was assessed by dual-
x-ray absorptiometry (Lunar Prodigy; GE
Lunar, Madison, WI) to measure fat-free
mass,fatmass,andpercentageoffatmass.
Analytical methods
Plasma insulin and C-peptide were mea-
suredinduplicatebydouble-antibodyra-
dioimmunoassays (Linco Research, St.
Charles, MO). Intra-assay variation was
4.9 and 2.4%, and inter-assay variation
was 5.9 and 7.1%, respectively. Plasma
glucose was monitored immediately after
blood withdrawal with an Analox GM9
glucose-analyzer (Beckman Instruments,
Fullerton, CA).
Plasma glucose enrichment due to
6,6-D-glucose was determined by gas
chromatography-mass spectrometry on a
gas chromatograph 5890/mass spectrom-
eter 5972 (Hewlett Packard, Palo Alto,
CA) equipped with a 30-m capillary col-
umn,asdescribedbyWolfe(13).Inbrief,
100lofplasmawasdeproteinizedusing
2 ml of cold methanol, and the superna-
tant was dried and derivatized using ace-
tic anhydride-pyridine (1:1) to form
penta-acetate glucose. The samples were
then dried again and dissolved with ethyl
acetate for injection into the gas chro-
matograph-mass spectrometer. The frag-
ments 200, 201, and 202 were
monitored, and enrichment was calcu-
lated as the ratio of 202 to 200. C10 anal-
ysis was performed as described
previously (14).
Calculations
A physiological and isotopic steady state
wasachievedduringthelast20minofthe
basal period and of the meal period;
therefore, the glucose rate of appearance
(Ra), which is equivalent to endogenous
glucose production, and rate of disap-
pearance (Rd) were calculated as the
tracer infusion rate divided by the tracer-
to-tracee ratio. During the meal, glucose
non–steady-state conditions prevail, and,
thus, Ra and Rd were calculated using the
Steele equation (15). Glucose ﬂux rates
are expressed per kilogram of body
weight. Glucose clearance was calculated
as Rd divided by plasma glucose concen-
tration. AUCs of glucose and insulin con-
centrations and of glucose Ra and
clearance were calculated using the trap-
ezoidal method. AUC of meal glucose
clearancewasnormalizedtoAUCofinsu-
lin to account for different insulin con-
centrations observed during the three
tests.Insulinsecretionratewascomputed
by C-peptide deconvolution (16).
Cell culture and glucose uptake
L6myoblastsweregrownandmaintained
in 	-minimal essential medium contain-
ing 2% FBS and 1% antibiotic-antimy-
cotic mixture in an atmosphere of 5%
CO2 at 37°C as described elsewhere
(17,18). The cells were cultivated over-
night in 12-well plates with or without
0.2 mmol/l albumin-bound C10 and se-
rum starved for 4 h before being incu-
bated for 20 min with 10 nmol/l insulin.
Subsequently, myoblasts were washed
twice, and glucose transport was assayed
in HEPES-buffered saline solution (140
mmol/l NaCl, 20 mmol/l HEPES-sodium,
2.5 mmol/l MgSO4, 1 mmol/l CaCl2, and
5 mmol/l KCl, pH 7.4) containing 10 M
2-deoxy-D-glucose (0.5 Ci ml
1 2-de-
oxy-D-[
3H]glucose). The incubation me-
diumwasaspirated,thecellswerewashed
with ice-cold saline, and 1 ml of NaOH
Table 1—Mixed meal composition
Carbohydrates Proteins Lipids Sebacic acid
Control (450 kcal) 50 15 35 0
10 g C10 (450 kcal 
 60 kcal from C10 44 13 31 12
23 g C10 (450 kcal) 50 15 0 35
Data are kcal%.
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lysates were transferred to scintillation vi-
alsforradioactivitycounting.Nonspeciﬁc
uptake was determined in the presence of
cytochalasin B (10 M) and was sub-
tracted from all values.
Immunoprecipitation and Western
blot
To measure the total GLUT content, cell
lysates were subjected to 10% SDS-PAGE
and Western blotting (19). Filters were
incubated with GLUT4 antibodies (Ab-
nova, Prodotti Gianni, Milano, Italy) for
14 h at 4°C and then with peroxidated
anti-antibodies (Amersham Biosciences,
Cologno Monzese, Italy) for1ha troom
temperature. GLUT4 was ﬁnally revealed
by detection of chemoluminescence with
autoradiography.
Statistical analysis
DataarepresentedasmeansSD,unless
otherwise speciﬁed. For the clinical study
differencesamongthethreesessionswere
analyzed by nonparametric (Wilcoxon’s
signed-rank test) tests for paired samples
corrected for Bonferroni inference. Anal-
yses were performed using SPSS for Win-
dows (version 13.0; SPSS, Chicago, IL).
Signiﬁcance was accepted at P  0.05.
For the in vitro study, Student’s t test
was used to evaluate the signiﬁcance of
the effect of sebacic acid and insulin on
glucose transport. Results are expressed
as means  SD of ﬁve different experi-
ments, each performed in triplicate; SE is
reported for percent values.
RESULTS— Type 2 diabetic patients
(ﬁve women and ﬁve men) and control
subjects (four women and six men) were
matched for sex distribution, age (52.1 
6.98 vs. 47.2  6.03 years), and BMI
(27.98  4.08 vs. 26.63  3.03 kg/m
2).
Diabetic subjects were insulin resistant
with a Matsuda index of 5.65  1.41
compared with 15.29  2.63 in control
subjects (P  0.01).
All subjects ingested a mixed meal
(see RESEARCH DESIGN AND METHODS)contain-
ing either 0 g (control) and an additional
10 g C10 or 23 g C10 as a substitute of
dietary fats. The time courses of plasma
glucose and insulin in healthy control
subjects are shown in Fig. 1. The inges-
tion of C10 together with the meal re-
duced to some extent the glycemic peak,
but the glucose incremental AUC was sig-
niﬁcantly reduced only after 23 g C10
(Fig.2).Theinsulinpeaklevelwasclearly
reduced in both C10 groups, attaining a
valueof39%inthe10gC10groupand
71% in the 23 g C10 group (both P 
0.01) (Fig. 2).
The effect of C10 on plasma glucose
andinsulintimecoursesintype2diabetic
subjects is depicted in Fig. 1. A reduction
in the incremental glucose AUCs of 42
and 70% was observed in the 10 g C10
(P  0.037) and 23 g C10 (P  0.045)
groups, respectively (Fig. 2). Similarly to
what was observed in control subjects,
the incremental AUCs of insulin were de-
creased by 39% after 10 g C10 intake and
by64%after23gC10intake,respectively
(P  0.05) (Fig. 2C). Insulin secretion
ratewassimilaracrossthethreestudiesin
both type 2 diabetic patients and healthy
volunteers (Fig. 2).
Glucose Ra AUC was decreased simi-
larly in control and diabetic subjects after
C10 supplement (by 18% after 23 g
C10,P0.05)(Fig.2B),whereasglucose
clearance, which is an index of peripheral
insulinsensitivity,tendedtoincreaseafter
C10 supplementation, but reached statis-
tical signiﬁcance only in control subjects
after 23 g C10 (Fig. 2D).
As shown in Fig. 1, the concentration
of plasma C10 in diabetic patients (Fig.
1F) tended to be higher than that in con-
trol subjects (Fig. 1E), without reaching
statistical signiﬁcance, however, and
peaked at the same times. Furthermore,
in diabetic subjects the two curves (10 vs.
23 g) overlapped up to 320 min after the
meal, and then the concentration of C10
Figure1—Timecourseofplasmaglucose(millimolesperliter),insulin(picomolesperliter),and
sebacic acid concentrations (micrograms per milliliter) in healthy volunteers (left panels) and in
type2diabeticsubjects(rightpanels).f,controlstudy(0gC10);E,10gC10study;u,23gC10
study. Data are means  SE. As indicated by an arrow, the meal was ingested after 120 min of
6,6-D2-glucose-primed constant infusion to assess basal glucose Ra.
Iaconelli and Associates
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C10 compared with those fed 10 g C10.
The in vitro experiments were con-
ducted by using a concentration of 0.2
mmol/l,onthebasisoftheaverageplasma
concentration of C10 reached in humans
after C10 ingestion. In fact, a level of 40
g/ml plasma C10, whose molecular
weight is 202, corresponds to a concen-
tration of 0.198 mmol/l.
The insulin-dependent glucose up-
take from L6 cells increased more in the
presence of C10 (1.83  0.40 vs. 1.37 
0.28 pmol/mg   10 min [P  0.01] vs.
1.730.19vs.1.570.14pmol/mg 10
min[P0.019]),correspondingtoaper-
cent increase of 38.7  10.3% (mean 
SE)inpresenceofC10vs.11.45.4%in
itsabsence(P0.026).Thisincreasewas
associated with a 1.74  0.27-fold in-
creaseofglucosetransporterGLUT4(Fig.
3), in agreement with the slight increase
in glucose clearance observed after C10
(Fig. 2D).
CONCLUSIONS— The major ﬁnd-
ing of the present study is that sebacic
acid signiﬁcantly reduces postmeal glu-
cosecirculatinglevelsaswellasRainboth
healthy and insulin-resistant type 2 dia-
betic subjects. This reduction occurs
whenC10iseitheraddedtoamixedmeal
or substituted for lipids in an equivalent
caloric manner. The above effect is less
pronounced in healthy control subjects.
In L6 cells, C10 signiﬁcantly increases in-
sulin-mediated glucose uptake and
GLUT4 expression.
There is general agreement that post-
prandial hyperglycemia in type 2 diabetic
subjectsmainlydependsonadefectinthe
endogenous glucose output (EGO) sup-
pression. The defect in suppressing EGO
afteramealhasbeenestimatedtoaccount
for 35–50% of the excess circulating glu-
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tributed to impaired postprandial insulin
stimulation of peripheral glucose uptake.
The major contributor to the lack of EGO
suppression and, thus, to the exaggerated
postprandial hyperglycemia in diabetes
seems to be an increase in gluconeogene-
sis (21).
Our study does not allow discrimi-
nating among systemicRaof ingested glu-
cose, postprandial endogenous glucose
production,andperipheraltissueuptake.
In fact, to measure the Ra of ingested glu-
cose, we should have used a double trac-
er: one infused, as we did, and the other
labeling the carbohydrate content in the
meal. However, also in this case the Ra of
meal-derived glucose would have been
inﬂuenced by a variety of factors, such as
the type of complex carbohydrates, the
rateofgastricemptyingandorocecaltran-
sit time, and the fraction extracted by the
liver, the latter being largely dependent
on the prevailing glucose and, to a lesser
extent, insulin concentrations. In this re-
gard, it is of note that when the meal is
composed of complex carbohydrates, the
glucose tracer can give a wide variability
of the estimates of initial splanchnic glu-
cose uptake as well as of the pattern of
endogenous glucose production, which
has been reported to be rapidly sup-
pressed in some studies but to show an
initial paradoxical rise followed by a sub-
sequent fall in others (22). Therefore,
with all the precautions of incomplete in-
formation, we can remark that sebacic
acid induces a signiﬁcant reduction in the
glucose Ra, which can be ascribed to a
reduced hepatic glucose output and/or to
reduced glucose absorption.
Apossiblemechanismthroughwhich
sebacic acid might reduce EGO after a
mealcouldberelatedtoitsmitochondrial
-oxidation with production of succinic
acid(10),whichentersthemitochondrial
tricarboxylic acid cycle. Reduced in vivo
mitochondrialfunctioninskeletalmuscle
underrestingconditionsaswellasduring
postexercise recovery has been observed
in type 2 diabetic subjects (23). This im-
paired mitochondrial oxidative capacity
seems to be attributable to a reduced mi-
tochondrial tricarboxylic acid cycle ﬂux
(24). C10 might overcome this defective
mitochondrial tricarboxylic acid function
in diabetic skeletal muscles by providing
succinic acid and thus increasing whole-
body glucose clearance, skeletal muscle
tissue being the major contributor to glu-
cose uptake.
In this regard, we have observed that
in L6 cells, 0.2 mmol/l C10 signiﬁcantly
increased glucose uptake by 30% com-
pared with insulin alone and increased
GLUT4 protein expression 1.7-fold,
probably improving insulin signaling and
the docking of GLUT4 to the cell mem-
brane. This in vitro effect of C10 might
partially explain the marked decrease in
plasma glucose concentrations because it
is well known that the skeletal muscle
mass represents the most important con-
sumer of glucose.
We note that a true dose-response ef-
fect of C10 on glucose disposal was not
present in our investigation. In this re-
gard, it is necessary to point out that, as
previouslydemonstrated(25),thewhole-
body rate of C10 tissue uptake in male
healthy volunteers was 180.9  4.5
mol/min, which equals 0.5 mg/kg
bodywt/minor2.1g/hinasubjectweigh-
ing 70 kg. Therefore, in the 5 h after C10
ingestion with the mixed meal, 10.5 g
would be metabolized, thus explaining
why the effects obtained with 10 or 23 g
were similar.
In summary, although more detailed
studies are required to elucidate the
mechanism of action of sebacic acid in
type 2 diabetes, this study provides rele-
vant clues about its effect in reducing glu-
cose circulating levels when added to
standard meals.
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